Celsion Co. (NASDAQ:CLSN) has been assigned a consensus rating of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $14.50.
Several equities analysts have commented on the company. Zacks Investment Research downgraded Celsion from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Oppenheimer initiated coverage on shares of Celsion in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price objective on the stock.
Celsion (NASDAQ:CLSN) opened at $2.35 on Friday. Celsion has a twelve month low of $1.24 and a twelve month high of $7.56. The company has a market capitalization of $37.75, a P/E ratio of -0.40 and a beta of 1.82.
A hedge fund recently bought a new stake in Celsion stock. Sabby Management LLC acquired a new position in Celsion Co. (NASDAQ:CLSN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned about 1.30% of Celsion at the end of the most recent quarter. Institutional investors and hedge funds own 4.00% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Celsion Co. (CLSN) Receives Average Rating of “Buy” from Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/04/celsion-co-clsn-receives-average-rating-of-buy-from-brokerages.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.